Heliyon. 2021 Jun 1;7(6):e07201. doi: 10.1016/j.heliyon.2021.e07201. eCollection 2021 Jun.
The identification of cannabinoid ligands Cannabidiol and O-1918 as inverse agonists of the orphan receptor GPR52 is reported. Detailed characterisation of GPR52 pharmacology and modelling of the proposed receptor interaction is described. The identification of a novel and further CNS pharmacology for the polypharmacological agent and marketed drug Cannabidiol is noteworthy.